An advanced treatment for skin cancer that combines immunotherapy with mRNA vaccine technology has shown promising outcomes in a late-stage trial, as stated by pharmaceutical giants Merck and Moderna in a recent press release.
The experimental therapy, known as intismeran, outperformed immunotherapy alone in reducing melanoma recurrence and halting cancer spread to other body parts in patients previously treated with melanoma surgery, the press release revealed.
Describing the results as “statistically significant and clinically meaningful improvements,” the announcement emphasized that the Phase 3 trial, which is the final stage before regulatory approval, is still ongoing, with the disclosed results stemming from an interim analysis.
While awaiting the full trial details, Dr. Marcus Butler, a leading medical oncologist at Toronto’s Princess Margaret Cancer Centre, expressed cautious optimism about the development, citing encouraging outcomes from an earlier Phase 2 study involving a smaller patient group. He stressed the importance of interpreting the results with prudence, stating that it is still early in the evaluation process.
Upon finalization, the complete trial data may lead to the treatment becoming available to Canadians, a process estimated to take over eight months, according to Dr. Ramy Saleh, an oncology associate professor at McGill University in Montreal.
Addressing the logistical challenges of scaling up a novel treatment globally, Saleh highlighted the need for collaboration among government, healthcare entities, and the industry to navigate operational complexities. Cost implications and public willingness to support such innovations were underscored as crucial considerations.
Melanoma, a prevalent form of cancer among Canadians aged 15 to 49, continues to pose a significant health threat, with approximately 11,300 new cases and 1,250 fatalities projected in Canada this year, according to the Canadian Cancer Society.
Publicly traded companies often disclose preliminary findings to adhere to market regulations and deter insider trading, as opposed to withholding data until the trial concludes. Following the announcement, Moderna’s shares surged by nearly 177%, with Merck also experiencing a 12.6% increase in stock value.
The treatment amalgamates Merck’s immunotherapy drug Keytruda with a personalized mRNA vaccine from Moderna, leveraging tumour samples to identify abnormal proteins (neoantigens) within cancer cells. This approach enables the immune system to target and eradicate cancer cells bearing these antigens, as explained by Dr. Lennard Lee, a medical oncologist and associate professor at Oxford.
Highlighting the dual action of the treatment, Lee emphasized that while immunotherapy enhances immune responses by removing checkpoints, mRNA vaccines instruct cells to combat cancer cells by recognizing and attacking specific antigens.
Noteworthy caveats and limitations of the trial include its focus on 1,137 high-risk patients with surgically treated Stage IIB-IV melanoma, with Canadian participants included in the study. Volunteers were randomly assigned to receive Keytruda with the personalized vaccine or Keytruda alone for a year, with no new safety concerns reported.
Concerns were raised regarding the potential immune stimulation by mRNA vaccines, not solely targeting melanoma antigens, which could impact the study’s outcome interpretation. Dr. Butler stressed the necessity for continued research, especially for later-stage melanoma patients, as previous studies yielded mixed results.
The evolving landscape of cancer treatment underscores the need for comprehensive studies and ongoing evaluation to determine the efficacy and safety of novel therapies in diverse patient populations and disease stages.